Newsfeed

This area is a possible form of presentation for the integration of news sources relating to listed companies.
The presentation level is a template based on short news services, where users can get a quick overview of the latest news. The detailed views enable further research if interested.

This newsfeed is a compilation of current news from direct connections of TopTier NewsWire services related to listed companies. This feed is for demonstration purposes only. Sector-specific news, public relations and product information can be accessed via the GICS portals > Sector Intelligence section.

CA14161Y2006
Reset filter
Do you already know our new terminal view? Click here.
FIGI: BBG00M0GNP68
CRDL
Cardiol Therapeutics Inc
GICS: Health Care · SECTOR: EQTY · SUB-SECTOR: - · THEMEFOLIO: $HLTH
NAME
Cardiol Therapeutics Inc
ISIN
CA14161Y2006
TICKER
CRDL
MIC
XTSX
REUTERS
CRDL.TO
BLOOMBERG
CRDL CN
Tue, 03.11.2026       Cardiol Therapeutics
CA14161Y2006

TORONTO, Nov. 3, 2026 /PRNewswire/ -- Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for heart disease, is pleased to announce that it has entered into a sales agreement (the "ATM Agreement") with Jefferies LLC (the "Sales...
Read more
Cardiol Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 03.11.2026       Cardiol Therapeutics
CA14161Y2006

TORONTO, Nov. 3, 2026 /CNW/ -- Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for heart disease, is pleased to announce that it has entered into a sales agreement (the "ATM Agreement") with Jefferies LLC (the "Sales Agent"...
Read more
Cardiol Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 23.09.2026       Cardiol Therapeutics
CA14161Y2006

Original 110-patient enrollment target achieved ahead of the Company's end-of-September guidance.The MAVERIC Steering Committee recommends expanding enrollment to up to 150 patients to capture sufficient events for a robust assessment of CardiolRx™'s potential to reduce recurrence risk. The recommendation follows a blinded review showing fewer-tha...
Read more
Cardiol Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 23.09.2026       Cardiol Therapeutics
CA14161Y2006

Original 110-patient enrollment target achieved ahead of the Company's end-of-September guidance.The MAVERIC Steering Committee recommends expanding enrollment to up to 150 patients to capture sufficient events for a robust assessment of CardiolRx™'s potential to reduce recurrence risk. The recommendation follows a blinded review showing fewer-tha...
Read more
Cardiol Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 16.09.2026       Cardiol Therapeutics
CA14161Y2006

Proceeds strengthen balance sheet ahead of pivotal Phase III MAVERIC trial data readout in recurrent pericarditis and extends cash runway into H1 2028.TORONTO, Sept. 16, 2026 /PRNewswire/ -- Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and anti-fib...
Read more
Cardiol Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 16.09.2026       Cardiol Therapeutics
CA14161Y2006

Proceeds strengthen balance sheet ahead of pivotal Phase III MAVERIC trial data readout in recurrent pericarditis and extends cash runway into H1 2028.TORONTO, Sept. 16, 2026 /CNW/ -- Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic t...
Read more
Cardiol Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 10.09.2026       Cardiol Therapeutics
CA14161Y2006

TORONTO, Sept. 10, 2026 /PRNewswire/ -- Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for heart disease, today announced that it has filed a preliminary short form base shelf prospectus (the "Shelf Prospectus") with the s...
Read more
Cardiol Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 10.09.2026       Cardiol Therapeutics
CA14161Y2006

TORONTO, Sept. 10, 2026 /CNW/ -- Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for heart disease, today announced that it has filed a preliminary short form base shelf prospectus (the "Shelf Prospectus") with the securiti...
Read more
Cardiol Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 09.09.2026       Cardiol Therapeutics
CA14161Y2006

TORONTO, Sept. 9, 2026 /PRNewswire/ -- Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for heart disease, is pleased to announce that it will participate in a Fireside Chat at the H.C. Wainwright 28th Annual Global Investme...
Read more
Cardiol Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 09.09.2026       Cardiol Therapeutics
CA14161Y2006

TORONTO, Sept. 9, 2026 /CNW/ -- Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for heart disease, is pleased to announce that it will participate in a Fireside Chat at the H.C. Wainwright 28th Annual Global Investment Conf...
Read more
Cardiol Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Wed, 05.08.2026       Cardiol Therapeutics
CA14161Y2006

TORONTO, Aug. 5, 2026 /CNW/ -- Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for heart disease, is pleased to announce that it will participate in a Fireside Chat at Canaccord Genuity's 46th Annual Growth Conference in Bo...
Read more
Cardiol Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 05.08.2026       Cardiol Therapeutics
CA14161Y2006

TORONTO, Aug. 5, 2026 /PRNewswire/ -- Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for heart disease, is pleased to announce that it will participate in a Fireside Chat at Canaccord Genuity's 46th Annual Growth Conferenc...
Read more
Cardiol Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 14.07.2026       Cardiol Therapeutics
CA14161Y2006

• Peer-reviewed JAHA publication strengthens the foundation for Cardiol's pivotal Phase III MAVERIC trial as enrollment nears completion.TORONTO, July 14, 2026 /CNW/ -- Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for he...
Read more
Cardiol Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 14.07.2026       Cardiol Therapeutics
CA14161Y2006

• Peer-reviewed JAHA publication strengthens the foundation for Cardiol's pivotal Phase III MAVERIC trial as enrollment nears completion.TORONTO, July 14, 2026 /PRNewswire/ -- Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies...
Read more
Cardiol Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 09.07.2026       Cardiol Therapeutics
CA14161Y2006

TORONTO, July 9, 2026 /CNW/ - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for heart disease, is pleased to announce that it will participate in a Fireside Chat at the B. Riley Securities Mind, Muscle & Vision Summit...
Read more
Cardiol Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 09.07.2026       Cardiol Therapeutics
CA14161Y2006

TORONTO, July 9, 2026 /PRNewswire/ - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for heart disease, is pleased to announce that it will participate in a Fireside Chat at the B. Riley Securities Mind, Muscle & Vision...
Read more
Cardiol Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 25.06.2026       Cardiol Therapeutics
CA14161Y2006

TORONTO, June 25, 2026 /PRNewswire/ - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for heart disease, announces the results from its Annual General Meeting of Shareholders (the "AGM") held virtually via live audio webcas...
Read more
Cardiol Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 25.06.2026       Cardiol Therapeutics
CA14161Y2006

TORONTO, June 25, 2026 /CNW/ - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for heart disease, announces the results from its Annual General Meeting of Shareholders (the "AGM") held virtually via live audio webcast on Ju...
Read more
Cardiol Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 23.06.2026       Cardiol Therapeutics
CA14161Y2006

TORONTO, June 23, 2026 /PRNewswire/ - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for heart disease, announces that the Company's virtual Annual General Meeting of Shareholders (the "AGM") will be webcast on June 24, 20...
Read more
Cardiol Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 23.06.2026       Cardiol Therapeutics
CA14161Y2006

TORONTO, June 23, 2026 /CNW/ - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for heart disease, announces that the Company's virtual Annual General Meeting of Shareholders (the "AGM") will be webcast on June 24, 2026, at...
Read more
Cardiol Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Thu, 14.05.2026       Cardiol Therapeutics
CA14161Y2006

TORONTO, May 14, 2026 /PRNewswire/ - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for heart disease, is pleased to announce that it will participate in a Fireside Chat at the H.C. Wainwright 4th Annual BioConnect Investo...
Read more
Cardiol Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 14.05.2026       Cardiol Therapeutics
CA14161Y2006

TORONTO, May 14, 2026 /CNW/ - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for heart disease, is pleased to announce that it will participate in a Fireside Chat at the H.C. Wainwright 4th Annual BioConnect Investor Confe...
Read more
Cardiol Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 07.05.2026       Cardiol Therapeutics
CA14161Y2006

Results demonstrate CardiolRx™ may represent a paradigm shift in the treatment of patients with recurrent pericarditis and further validate the ongoing Phase III trial, which recently surpassed 75% enrollment.TORONTO, ON, May 7, 2026 /PRNewswire/ - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life...
Read more
Cardiol Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 07.05.2026       Cardiol Therapeutics
CA14161Y2006

Results demonstrate CardiolRx™ may represent a paradigm shift in the treatment of patients with recurrent pericarditis and further validate the ongoing Phase III trial, which recently surpassed 75% enrollment.TORONTO, ON, May 7, 2026 /CNW/ - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life scienc...
Read more
Cardiol Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 28.04.2026       Cardiol Therapeutics
CA14161Y2006

Leading enrolling centers include Cleveland Clinic, three major campuses of the Mayo Clinic, Northwestern University, Massachusetts General Hospital, Columbia University–NewYork-Presbyterian, NYU Langone Health, Lenox Hill Hospital/Northwell Health, and Houston Methodist Hospital.Growing interest in MAVERIC is expected to support the activation of...
Read more
Cardiol Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 28.04.2026       Cardiol Therapeutics
CA14161Y2006

Leading enrolling centers include Cleveland Clinic, three major campuses of the Mayo Clinic, Northwestern University, Massachusetts General Hospital, Columbia University–NewYork-Presbyterian, NYU Langone Health, Lenox Hill Hospital/Northwell Health, and Houston Methodist Hospital.Growing interest in MAVERIC is expected to support the activation of...
Read more
Cardiol Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 14.04.2026       Cardiol Therapeutics
CA14161Y2006

Toronto, Ontario--(Newsfile Corp. - April 14, 2026) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease, is pleased to announce that Cardiol's President and Chief Executive Offic...
Read more
Cardiol Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 01.04.2026       Cardiol Therapeutics
CA14161Y2006

Initiated pivotal Phase III MAVERIC trial of CardiolRx™ in recurrent pericarditis and surpassed 50% patient enrollment, with full enrollment expected in Q2 2026.Reported positive Phase II ARCHER data showing CardiolRx™ significantly reduced left ventricular mass in patients with acute myocarditis; results published in ESC Heart Failure....
Read more
Cardiol Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 25.02.2026       Cardiol Therapeutics
CA14161Y2006

Toronto, Ontario--(Newsfile Corp. - February 25, 2026) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease, is pleased to announce that it will participate at the upcoming TD Cow...
Read more
Cardiol Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 10.02.2026       Cardiol Therapeutics
CA14161Y2006

Toronto, Ontario--(Newsfile Corp. - February 10, 2026) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease, today announced the publication of results from its Phase II ARCHER st...
Read more
Cardiol Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Fri, 23.01.2026       Cardiol Therapeutics
CA14161Y2006

Toronto, Ontario--(Newsfile Corp. - January 23, 2026) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease, today announced that it has closed its previously announced private pla...
Read more
Cardiol Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Fri, 16.01.2026       Cardiol Therapeutics
CA14161Y2006

TORONTO, Jan. 16, 2026 /CNW/ - Trading resumes in: Company: Cardiol Therapeutics Inc.TSX Symbol: CRDLAll Issues: YesResumption (ET): 9:00 AMCIRO can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts are implemented to ensure a fair and orderly market. CIRO is the national s...
Read more
Cardiol Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Fri, 16.01.2026       Cardiol Therapeutics
CA14161Y2006

Toronto, Ontario--(Newsfile Corp. - January 16, 2026) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease, today announced that it has entered into an agreement with a sole under...
Read more
Cardiol Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Fri, 16.01.2026       Cardiol Therapeutics
CA14161Y2006

Toronto, Ontario--(Newsfile Corp. - January 16, 2026) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease, today announced that it has entered into an agreement with Canaccord Ge...
Read more
Cardiol Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Fri, 16.01.2026       Cardiol Therapeutics
CA14161Y2006

TORONTO, Jan. 16, 2026 /CNW/ - The following issues have been halted by CIRO: Company: Cardiol Therapeutics Inc.TSX Symbol: CRDL All Issues: YesReason: Pending News Halt Time (ET): 8:10 AMCIRO can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts are implemented to ensure a...
Read more
Cardiol Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Fri, 16.01.2026       Cardiol Therapeutics
CA14161Y2006

Instrument ID [6186088] (CT9 - CA14161Y2006) suspended...
Read more
Cardiol Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 13.01.2026       Cardiol Therapeutics
CA14161Y2006

Clinical trial infrastructure fully operational in the U.S. with more than 15 leading cardiovascular centers actively enrolling patients.Activation of additional top-tier clinical sites in Europe and Canada underway, further accelerating enrollment momentum.Full enrollment expected in Q2 2026.Toronto, Ontario--(Newsfile Corp. - January 13, 2026) -...
Read more
Cardiol Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 17.12.2025       Cardiol Therapeutics
CA14161Y2006

Original-Research: Cardiol Therapeutics Inc - from First Berlin Equity Research GmbH 17.12.2025 / 14:38 CET/CEST Dissemination of a Research, transmitted by EQS News - a service of EQS Group. The issuer is solely responsible for the content of this research. The result of this research does not constitute investment advice or an invitation to co......
Read more
Cardiol Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 01.12.2025       Cardiol Therapeutics
CA14161Y2006

Phase II ARCHER trial showed a significant reduction in left ventricular (LV) mass (p=0.0117) and improvements in multiple key cardiac MRI (CMR) measures of structural heart recovery in patients with acute myocarditis.Results provide clinical evidence that CardiolRx™ reduces inflammation-driven structural damage in the heart, an important cau...
Read more
Cardiol Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 13.11.2025       Cardiol Therapeutics
CA14161Y2006

Once issued, this new U.S. patent covers the use of CardiolRx™ and CRD-38 for a broad range of cardiac disorders, including atherosclerosis and heart failure, significantly expanding intellectual property protection in the world's largest pharmaceutical market.This allowance fortifies Cardiol's global intellectual property portfolio, adding t...
Read more
Cardiol Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 05.11.2025       Cardiol Therapeutics
CA14161Y2006

The ESC M&PD meeting brings together the world's experts working to improve the treatment of myocarditis and pericarditis.Presentation to provide comprehensive findings from the ARCHER trial following the reporting of topline results demonstrating a notable improvement in extracellular volume and a significant reduction in left ventricular mass...
Read more
Cardiol Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 23.10.2025       Cardiol Therapeutics
CA14161Y2006

Original-Research: Cardiol Therapeutics Inc - from First Berlin Equity Research GmbH 23.10.2025 / 12:51 CET/CEST Dissemination of a Research, transmitted by EQS News - a service of EQS Group. The issuer is solely responsible for the content of this research. The result of this research does not constitute investment advice or an invitation to co......
Read more
Cardiol Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 21.10.2025       Cardiol Therapeutics
CA14161Y2006

MAVERIC Phase III pivotal trial of orphan drug candidate CardiolRx™ in recurrent pericarditis is fully funded through to a planned New Drug Application submission with the FDA.New data from the ARCHER trial, highlighting the magnitude of reduction in left ventricular (LV) mass and the read through to heart failure, to be presented at a cardio...
Read more
Cardiol Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 20.10.2025       Cardiol Therapeutics
CA14161Y2006

TORONTO, Oct. 20, 2025 /CNW/ - Trading resumes in: Company: Cardiol Therapeutics Inc. TSX Symbol: CRDL All Issues: Yes Resumption (ET): 8:00 AM CIRO can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-liste...
Read more
Cardiol Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 20.10.2025       Cardiol Therapeutics
CA14161Y2006

Instrument ID [6186088] (CT9 - CA14161Y2006) suspended...
Read more
Cardiol Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Fri, 17.10.2025       Cardiol Therapeutics
CA14161Y2006

MAVERIC Phase III pivotal trial of orphan drug candidate CardiolRx™ in recurrent pericarditis is fully funded through to a planned New Drug Application submission with the FDA.New data from the ARCHER trial, highlighting the magnitude of reduction in left ventricular (LV) mass and the read through to heart failure, to be presented at a cardio...
Read more
Cardiol Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Fri, 17.10.2025       Cardiol Therapeutics
CA14161Y2006

TORONTO, Oct. 17, 2025 /CNW/ - The following issues have been halted by CIRO: Company: Cardiol Therapeutics Inc. TSX Symbol: CRDL All Issues: Yes Reason: Pending News Halt Time (ET): 4:12 PM CIRO can make a decision to impose a temporar...
Read more
Cardiol Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 12.08.2025       Cardiol Therapeutics
CA14161Y2006

Original-Research: Cardiol Therapeutics Inc - from First Berlin Equity Research GmbH 12.08.2025 / 13:31 CET/CEST Dissemination of a Research, transmitted by EQS News - a service of EQS Group. The issuer is solely responsible for the content of this research. The result of this research does not constitute investment advice or an invitation to co......
Read more
Cardiol Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 11.08.2025       Cardiol Therapeutics
CA14161Y2006

Toronto, Ontario--(Newsfile Corp. - August 11, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, is pleased to announce that it will participate in a Fireside Chat at...
Read more
Cardiol Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 22.07.2025       Cardiol Therapeutics
CA14161Y2006

ARCHER is designed to assess the impact of CardiolRx™ on cardiac magnetic resonance imaging parameters that measure heart dysfunction and edema/fibrosis-key measurements used to predict prognosis in myocarditis patients.Acute myocarditis is a potentially life-threatening condition affecting the heart muscle (myocardium) and is characterized b...
Read more
Cardiol Therapeutics
Technical Analysis Termsheets Terminal
Permalink